Cargando…

Risk factors of infective endocarditis in persons who inject drugs

BACKGROUND: The rising incidence of infective endocarditis (IE) among people who inject drugs (PWID) has been a major concern across North America. The coincident rise in IE and change of drug preference to hydromorphone controlled-release (CR) among our PWID population in London, Ontario intrigued...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Meera, Wong, Ryan, Ball, Laura, Puka, Klajdi, Tan, Charlie, Shojaei, Esfandiar, Koivu, Sharon, Silverman, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275611/
https://www.ncbi.nlm.nih.gov/pubmed/32503573
http://dx.doi.org/10.1186/s12954-020-00378-z
_version_ 1783542821976801280
author Shah, Meera
Wong, Ryan
Ball, Laura
Puka, Klajdi
Tan, Charlie
Shojaei, Esfandiar
Koivu, Sharon
Silverman, Michael
author_facet Shah, Meera
Wong, Ryan
Ball, Laura
Puka, Klajdi
Tan, Charlie
Shojaei, Esfandiar
Koivu, Sharon
Silverman, Michael
author_sort Shah, Meera
collection PubMed
description BACKGROUND: The rising incidence of infective endocarditis (IE) among people who inject drugs (PWID) has been a major concern across North America. The coincident rise in IE and change of drug preference to hydromorphone controlled-release (CR) among our PWID population in London, Ontario intrigued us to study the details of injection practices leading to IE, which have not been well characterized in literature. METHODS: A case–control study, using one-on-one interviews to understand risk factors and injection practices associated with IE among PWID was conducted. Eligible participants included those who had injected drugs within the last 3 months, were > 18  years old and either never had or were currently admitted for an IE episode. Cases were recruited from the tertiary care centers and controls without IE were recruited from outpatient clinics and addiction clinics in London, Ontario. RESULTS: Thirty three cases (PWID IE+) and 102 controls (PWID but IE-) were interviewed. Multivariable logistic regressions showed that the odds of having IE were 4.65 times higher among females (95% CI 1.85, 12.28; p = 0.001) and 5.76 times higher among PWID who did not use clean injection equipment from the provincial distribution networks (95% CI 2.37, 14.91; p < 0.001). Injecting into multiple sites and heating hydromorphone-CR prior to injection were not found to be significantly associated with IE. Hydromorphone-CR was the most commonly injected drug in both groups (90.9% cases; 81.4% controls; p = 0.197). DISCUSSION: Our study highlights the importance of distributing clean injection materials for IE prevention. Furthermore, our study showcases that females are at higher risk of IE, which is contrary to the reported literature. Gender differences in injection techniques, which may place women at higher risk of IE, require further study. We suspect that the very high prevalence of hydromorphone-CR use made our sample size too small to identify a significant association between its use and IE, which has been established in the literature.
format Online
Article
Text
id pubmed-7275611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72756112020-06-08 Risk factors of infective endocarditis in persons who inject drugs Shah, Meera Wong, Ryan Ball, Laura Puka, Klajdi Tan, Charlie Shojaei, Esfandiar Koivu, Sharon Silverman, Michael Harm Reduct J Research BACKGROUND: The rising incidence of infective endocarditis (IE) among people who inject drugs (PWID) has been a major concern across North America. The coincident rise in IE and change of drug preference to hydromorphone controlled-release (CR) among our PWID population in London, Ontario intrigued us to study the details of injection practices leading to IE, which have not been well characterized in literature. METHODS: A case–control study, using one-on-one interviews to understand risk factors and injection practices associated with IE among PWID was conducted. Eligible participants included those who had injected drugs within the last 3 months, were > 18  years old and either never had or were currently admitted for an IE episode. Cases were recruited from the tertiary care centers and controls without IE were recruited from outpatient clinics and addiction clinics in London, Ontario. RESULTS: Thirty three cases (PWID IE+) and 102 controls (PWID but IE-) were interviewed. Multivariable logistic regressions showed that the odds of having IE were 4.65 times higher among females (95% CI 1.85, 12.28; p = 0.001) and 5.76 times higher among PWID who did not use clean injection equipment from the provincial distribution networks (95% CI 2.37, 14.91; p < 0.001). Injecting into multiple sites and heating hydromorphone-CR prior to injection were not found to be significantly associated with IE. Hydromorphone-CR was the most commonly injected drug in both groups (90.9% cases; 81.4% controls; p = 0.197). DISCUSSION: Our study highlights the importance of distributing clean injection materials for IE prevention. Furthermore, our study showcases that females are at higher risk of IE, which is contrary to the reported literature. Gender differences in injection techniques, which may place women at higher risk of IE, require further study. We suspect that the very high prevalence of hydromorphone-CR use made our sample size too small to identify a significant association between its use and IE, which has been established in the literature. BioMed Central 2020-06-05 /pmc/articles/PMC7275611/ /pubmed/32503573 http://dx.doi.org/10.1186/s12954-020-00378-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shah, Meera
Wong, Ryan
Ball, Laura
Puka, Klajdi
Tan, Charlie
Shojaei, Esfandiar
Koivu, Sharon
Silverman, Michael
Risk factors of infective endocarditis in persons who inject drugs
title Risk factors of infective endocarditis in persons who inject drugs
title_full Risk factors of infective endocarditis in persons who inject drugs
title_fullStr Risk factors of infective endocarditis in persons who inject drugs
title_full_unstemmed Risk factors of infective endocarditis in persons who inject drugs
title_short Risk factors of infective endocarditis in persons who inject drugs
title_sort risk factors of infective endocarditis in persons who inject drugs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275611/
https://www.ncbi.nlm.nih.gov/pubmed/32503573
http://dx.doi.org/10.1186/s12954-020-00378-z
work_keys_str_mv AT shahmeera riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT wongryan riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT balllaura riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT pukaklajdi riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT tancharlie riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT shojaeiesfandiar riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT koivusharon riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs
AT silvermanmichael riskfactorsofinfectiveendocarditisinpersonswhoinjectdrugs